Skip to main content
AmigoFish

Oxford based Alethio Therapeutics unveiled a $90M Series A today to advance its therapies for myeloproliferative neoplasms, and also announced for the first time that ATX-011's target will be G6B

From BiotechTV - News · · 14 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

CEO Rohit Batta describes the unmet need in myeloproliferative neoplasms and the rational for targeting G6B, a protein expressed on platelets and megakaryocytes. Their pre-clinical work just earned Alethio an oral presentation at the upcoming ASH Annual Meeting.

Back to BiotechTV - News · Report a problem